F 528
Alternative Names: F-528Latest Information Update: 29 Mar 2024
At a glance
- Originator GNI
- Developer Gyre Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 26 Mar 2024 Pharmacodynamics and adverse events data from in vivo study in Chronic obstructive pulmonary disease released by Gyre Therapeutics
- 31 Dec 2023 Gyre Therapeutics has one Patent Cooperation Treaty patent application and one patent application with for F 528 in the People's Republic of China (PRC), Japan, Europe and the US (Gyre Therapeutics 10-K, April 2024)
- 31 Dec 2023 Pharmacodynamics data from a preclinical study in Chronic obstructive pulmonary disease released by Gyre Therapeutics (Gyre Therapeutics 10-K, April 2024)